Targeted drug delivery across the blood brain barrier in Alzheimer's disease

Current Pharmaceutical Design

Volumn 19, Issue 37, 2013, Pages 6635-6646

  Rocha, Sandra ^a  

^a CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Alzheimer's disease; Blood brain barrier; Brain drug targeting; Liposomes; Monoclonal antibodies; Parenteral route administration; Polymeric nanoparticles; Therapeutic peptides

Indexed keywords

1 VINYL 2 PYRROLIDINONE; ACRYLIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CELL PENETRATING PEPTIDE; CHITOSAN; CLIOQUINOL; CURCUMIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DONEPEZIL; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL; MANNITOL; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX 26; NANOCARRIER; PEPTIDE DERIVATIVE; POLY(BUTYL 2 CYANOACRYLATE); POLY(N ISOPROPYLACRYLAMIDE); POLYGLACTIN; POLYLACTIDE; POLYMER; POLYSORBATE 80; PUTRESCINE; RIVASTIGMINE; TACRINE; TRYPAN BLUE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; IN VIVO STUDY; LIPOSOMAL DELIVERY; MACROMOLECULE; MATERIAL COATING; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE; VALIDATION STUDY;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84887922844     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990613     Document Type: Article

References (110)

1. Forstl H, Kurz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 288-90.
2. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487-98.
3. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol 2007; 8: 101-12.
4. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010; 88: 475-86.
5. Pardridge WA. Alzheimer's disease drug development and the problem of the blood-brain barrier. Alzheimers Dement 2009; 5: 427-32.
6. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
7. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
8. Roth LJ, Barlow CF. Drugs in brain-autoradiography and radioassay techniques permit analysis of penetration by labeled drugs. Science 1961; 134: 22-31.
9. Banks WA. Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier. Adv Drug Deliv Rev 2012; 64: 629-39.
10. Roney C, Kulkarni P, Arora V, et al. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease. J Control Release 2005; 108: 193-214.
11. Brambilla D, Le Droumaguet B, Nicolas J, et al. Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomed Nanotechnol Biol Med 2011; 7: 521-40.
12. Sahni JK, Doggui S, Ali J, Baboota S, Dao L, Ramassamy C. Neurotherapeutic applications of nanoparticles in Alzheimer's disease. J Control Release 2011; 152: 208-31.
13. Neuwelt EA. Mechanisms of disease: the blood-brain barrier. Neurosurgery 2004; 54: 131-40.
14. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
15. Bickel U. Delivery of chemically-modified peptides and proteins through the blood-brain-barrier. Chimia 1995; 49: 386-95.
16. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247-79.
17. Herve F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. Aaps J 2008; 10: 455-72.
18. Maggio JE, Stimson ER, Ghilardi JR, et al. Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992; 89: 5462-6.
19. Saito Y, Buciak J, Yang J, Pardridge WM. Vector-mediated delivery of I-125 labeled beta-amyloid peptide A-Beta(1-40) through the blood-brain-barrier and binding to Alzheimer-Disease amyloid of the A-Beta(1-40)/vector complex. Proc Natl Acad Sci USA 1995; 92: 10227-31.
20. Poduslo JF, Curran GL, Sanyal B, Selkoe DJ. Receptor-mediated transport of human amyloid beta-protein 1-40 and 1-42 at the blood-brain barrier. Neurobiol Dis 1999; 6: 190-9.
21. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci 1994; 55: 1643-50.
22. Zlokovic BV. Cerebrovascular transport of Alzheimer's amyloid beta and apolipoproteins J and E: Possible anti-amyloidogenic role of the blood-brain barrier. Life Sci 1996; 59: 1483-97.
23. Mackic JB, Bading J, Ghiso J, et al. Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vasc Pharmacol 2002; 38: 303-13.
24. Ito S, Ohtsuki S, Kamiie J, Nezu Y, Terasaki T. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes. J Neurochem 2007; 103: 2482-90.
25. Wu DF, Yang J, Pardridge WM. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J Clin Invest 1997; 100: 1804-12.
26. Lee HJ, Pardridge WM. Drug targeting to the brain using avidinbiotin technology in the mouse (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease). J Drug Target 2000; 8: 413-24.
27. Lee HJ, Zhang Y, Zhu CN, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in Transgenic mice with an A beta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002; 22: 223-31.
28. Zhou QH, Lu JZ, Hui EKW, Boado RJ, Pardridge WM. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug Chem 2011; 22: 1611-8.
29. Sumbria RK, Boado RJ, Pardridge WM. Imaging amyloid plaque in Alzheimer's Disease brain with a biotinylated A-beta peptide radiopharmaceutical conjugated to an IgG-avidin fusion protein. Bioconjug Chem 2012; 23: 1318-21.
30. Ono M, Cheng Y, Kimura H, et al. Novel F-18-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of beta-amyloid plaques in Alzheimer's brains. J Med Chem 2011; 54: 2971-9.
31. Boado RJ, Zhang Y, Xia CF, Wang Y, Pardridge WM. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjugate Chem 2008; 19: 731-9.
32. Wengenack TM, Curran GL, Poduslo JF. Targeting Alzheimer amyloid plaques in vivo. Nat Biotechnol 2000; 18: 868-72.
33. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11: 315-29.
34. Poduslo JF, Curran GL, Peterson JA, et al. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 2004; 43: 6064-75.
35. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloidbeta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-7.
36. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-82.
37. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-5.
38. Lambert MP, Viola KL, Chromy BA, et al. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 2001; 79: 595-605.
39. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-9.
40. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001; 98: 8850-5.
41. Lombardo JA, Stern EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci 2003; 23: 10879-83.
42. Deane R, Sagare A, Hamm K, et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci 2005; 25: 11495-503.
43. Solomon B, Koppel R, Frankel D, Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997; 94: 4109-12.
44. Rabchevsky AG, Degos JD, Dreyfus PA. Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 1999; 832: 84-96.
45. Namer IJ, Steibel J. Antibody directed against mannan of the Mycobacterium tuberculosis cell envelope provokes blood-brain barrier breakdown. J Neuroimmunol 2000; 103: 63-68.
46. Birmingham K, Frantz S. Set back to Alzheimer vaccine studies. Nat Med 2002; 8: 199-200.
47. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-52.
48. Jancso G, Domoki F, Santha P, et al. Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 1998; 253: 139-41.
49. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 1999; 818: 105-17.
50. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002; 298: 1379.
51. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004; 1: 24.
52. Banks WA. Are the extracelluar pathways a conduit for the delivery of therapeutics to the brain? Curr Pharm Des 2004; 10: 1365-70.
53. Poduslo JF, Curran GL, Wengenack TM, Malester B, Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's Disease. Neurobiol Dis 2001; 8: 555-567.
54. Banks WA, Farr SA, Morley JE, Wolf KM, Geylis V, Steinitz M. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer's disease: an agerelated selective uptake with reversal of learning impairment. Exp Neurol 2007; 206: 248-56.
55. Boado RJ, Zhang YF, Zhang Y, Xia CF, Pardridge WM. Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and A beta fibril disaggregation. Bioconjug Chem 2007; 18: 447-55.
56. Zhang Y, Pardridge WM. Mediated efflux of IgG molecules from brain to blood across the blood-brain barrier. J Neuroimmunol 2001; 114: 168-72.
57. Garg A, Balthasar JP. Investigation of the influence of FcRn on the distribution of IgG to the brain. Aaps J 2009; 11: 553-7.
58. Poduslo JF, Ramakrishnan M, Holasek SS, et al. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007; 102: 420-33.
59. Sarkar G, Curran GL, Mahlum E, et al. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS ONE 2011; 6: e28881.
60. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004; 303: 1818-22.
61. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2008; 83: 761-9.
62. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005; 2: 108-19.
63. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005; 2: 99-107.
64. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64: 686-700.
65. Huwyler J, Wu DF, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-9.
66. Huwyler J, Yang J, Pardridge WM. Receptor mediated delivery of daunomycin using immunoliposomes: Pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 1997; 282: 1541-6.
67. Markoutsa E, Papadia K, Clemente C, Flores O, Antimisiaris SG. Anti-A beta-MAb and dually decorated nanoliposomes: Effect of A beta 1-42 peptides on interaction with hCMEC/D3 cells. Eur J Pharm Biopharm 2012; 81: 49-56.
68. Markoutsa E, Pampalakis G, Niarakis A, et al. Uptake and permeability studies of BBB-targeting immunoliposomes using the hCMEC/D3 cell line. Eur J Pharm Biopharm 2011; 77: 265-74.
69. Muhs A, Hickman DT, Pihlgren M, et al. Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. Proc Natl Acad Sci USA 2007; 104: 9810-5.
70. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain-barrier with colloidal polymer particles (nanoparticles). Brain Res 1995; 674: 171-4.
71. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008; 70: 75-84.
72. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res 2008; 1200: 159-68.
73. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010; 76: 189-99.
74. Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wires Nanomed Nanobiol 2010; 2: 35-47.
75. Sun M, Gao Y, Guo CY, et al. Enhancement of transport of curcumin to brain in mice by poly(n-butylcyanoacrylate) nanoparticle. J Nanopart Res 2010; 12: 3111-22.
76. Roney CA, Arora V, Kulkarni PV, Antich PP, Bonte FJ. Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease. Int J Alzheimers Dis 2009; 2009.
77. Koffie RM, Farrar CT, Saidi LJ, William CM, Hyman BT, Spires-Jones TL. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc Natl Acad Sci USA 2011; 108: 18837-42.
78. Siegemund T, Paulke BR, Schmiedel H, et al. Thioflavins released from nanoparticles target fibrillar amyloid beta in the hippocampus of APP/PS1 transgenic mice. Int J Dev Neurosci 2006; 24: 195-201.
79. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001; 47: 65-81.
80. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 1999; 16: 1836-42.
81. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409-16.
82. Zhang SJ, Wu LX. Amyloid-beta associated with chitosan nanocarrier has favorable immunogenicity and permeates the BBB. Aaps Pharmscitech 2009; 10: 900-5.
83. Wilson B, Samanta MK, Santhi K, Kumar KPS, Ramasamy M, Suresh B. Chitosan nanoparticles as a new delivery system for the anti-Alzheimer drug tacrine. Nanomed-Nanotechnol 2010; 6: 144-52.
84. Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res 2008; 25: 2674-84.
85. Zhang PC, Chen LL, Gu WW, Xu ZH, Gao Y, Li YP. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007; 28: 1882-8.
86. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials 2010; 31: 908-15.
87. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005; 107: 428-48.
88. Ray B, Bisht S, Maitra A, Maitra A, Lahiri DK. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc (TM) in the neuronal cell culture and animal model: Implications for Alzheimer's Disease. J Alzheimers Disease 2011; 23: 61-77.
89. Sun N, Funke SA, Willbold D. A Survey of peptides with effective therapeutic potential in Alzheimer's Disease rodent models or in human clinical studies. Mini-Rev Med Chem 2012; 12: 388-98.
90. Funke SA, Willbold D. Peptides for therapy and diagnosis of Alzheimer's disease. Curr Pharm Des 2012; 18: 755-67.
91. Findeis MA. Peptide inhibitors of beta amyloid aggregation. Curr Top Med Chem 2002; 2: 417-23.
92. Doig AJ. Peptide inhibitors of beta-amyloid aggregation. Curr Opin Drug Disc 2007; 10: 533-9.
93. Matsuoka Y, Jouroukhin Y, Gray AJ, et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008; 325: 146-53.
94. Soto C, Kindy MS, Baumann M, Frangione B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem Biophys Res Commun 1996; 226: 672-80.
95. Poduslo JF, Curran GL, Kumar A, Frangione B, Soto C. beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J Neurobiol 1999; 39: 371-82.
96. Permanne B, Adessi C, Saborio GP, et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J 2002; 16: 860-+.
97. Adessi C, Frossard MJ, Boissard C, et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease. J Biol Chem 2003; 278: 13905-11.
98. Chacon MA, Barria MI, Soto C, Inestrosa NC. beta-sheet breaker peptide prevents A beta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatr 2004; 9: 953-961.
99. Rocha S, Cardoso I, Borner H, Pereira MC, Saraiva MJ, Coelho M. Design and biological activity of beta-sheet breaker peptide conjugates. Biochem Biophys Res Commun 2009; 380: 397-401.
100. Datki Z, Papp R, Zadori D, et al. In vitro model of neurotoxicity of Abeta 1-42 and neuroprotection by a pentapeptide: irreversible events during the first hour. Neurobiol Dis 2004; 17: 507-15.
101. Szegedi V, Fulop L, Farkas T, et al. Pentapeptides derived from Abeta 1-42 protect neurons from the modulatory effect of Abeta fibrils--an in vitro and in vivo electrophysiological study. Neurobiol Dis 2005; 18: 499-508.
102. Juhasz G, Marki A, Vass G, et al. An intraperitoneally administered pentapeptide protects against Abeta (1-42) induced neuronal excitation in vivo. J Alzheimers Dis 2009; 16: 189-96.
103. Findeis MA, Phillips K, Olson GL, Self C. 2003. Modulators of beta-amyloid peptide aggregation. United States. Praecis Pharmaceuticals Inc. (Waltham, MA). 6610658. http://www. freepatentsonline. com/6610658. html.
104. PRAECIS Pharmaceuticals Inc. Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's Disease. In: ClinicalTrials. gov [Internet]. 2004-[cited 2012 Oct 10]. Available from: http://clinicaltrials. gov/ct2/show/study/NCT00100334. NLM Identifier: NCT00100334.
105. Sadowski M, Pankiewicz J, Scholtzova H, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 2004; 165: 937-48.
106. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, Gazit E. Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl 2009; 48: 1981-6.
107. Aileen Funke S, van Groen T, Kadish I, et al. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice. ACS Chem Neurosci 2010; 1: 639-48.
108. Liu H, Funke SA, Willbold D. Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model. Rejuvenation Res 2010; 13: 210-3.
109. Handattu SP, Garber DW, Monroe CE, et al. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol Dis 2009; 34: 525-34.
110. Jain KK. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 2012; 7: 1225-33.